Upon joining the study, you will be required to provide written informed consent. If you are unable to provide consent, a legal representative must do so on your behalf, and you will need to give your assent as per local regulations.

You must have a reliable and consistent parent, legal guardian, or caregiver during the study to assist with the process.

An initial assessment will be conducted to ensure you meet the criteria for participation. This includes having satisfactorily completed a previous study and having a diagnosis of developmental and epileptic encephalopathy (DEE).

The assessment will also confirm your ability to comply with study requirements, such as completing diaries throughout the study.

You will receive the study medication, bexicaserin, in the form of an oral solution. This medication can be taken orally or through a nasogastric tube or percutaneous endoscopic gastrostomy tube if necessary.

The dosage, frequency, and duration of administration will be determined by the study protocol and your healthcare provider.

Throughout the study, you will undergo regular monitoring to evaluate the safety and tolerability of the medication. This includes checking for any side effects, conducting physical examinations, and monitoring vital signs such as heart rate and blood pressure.

Additional assessments will include laboratory tests, growth measurements, and electrocardiograms (ECGs) to ensure your well-being.

You, or your caregiver, will be required to maintain a diary to record the frequency of seizures and any other relevant information. This will help in assessing the effectiveness of the treatment.

The diary will be reviewed regularly to track changes in seizure frequency and to adjust treatment if necessary.

At the end of the study, a final evaluation will be conducted to assess the overall impact of the medication on your condition.

This will include a review of all collected data, including seizure frequency, side effects, and any changes in your health status.